Role of microRNAs in Mediating Angiotensin II Effects on Inflammation and ER stress
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE147935 | GEO | 2020/07/15
REPOSITORIES: GEO
Similar Datasets
Project description:Role of microRNAs in Mediating Angiotensin II Effects on Inflammation and ER stress
| PRJNA622575 | ENA
Project description:The brain renin-angiotensin system (RAS) stimulates resting metabolic rate in part through a mechanism involving suppression of the circulating RAS. This effect appears to be mediated through a reduction in angiotensin AT2 receptor (AT2R) signaling within inguinal fat. To examine the molecular mechanisms underlying this effect, mice with hyperactivity of the brain RAS (“sRA” mice, expressing human renin via the synapsin promoter and human angiotensinogen via its own promoter) and littermate controls were chronically infused with vehicle or the AT2R specific agonist, CGP-42112a (CGP, 90 ng/hr, 8 wk, sc). To identify altered signaling pathways, total RNA was isolated from inguinal adipose tissue and transcript abundance was quantitated by RNA-Seq.
2016-12-07 | GSE77214 | GEO
Project description:LC-MS/MS Proteomics was performed to determine proteomic differences between colon adenocarcinoma (CA) tissues and patient-matched normal colon tissues, CA-derived primary cell lines and NC-derived primary cells, and between LGCA tissues and cell lines and HGCA tissues and cell lines. Biological processes which may link the renin-angiotensin system and CA were investigated, revealing enrichment of various signalling pathways that may play roles in CA onset and progression directly or via the renin-angiotensin system.
2022-08-12 | PXD024449 | Pride
Project description:High blood pressure is one of the major public health problems which causes severe disorders in several tissues including the human kidney. One of the most important signaling pathways associated with the regulation of blood pressure is the renin-angiotensin system (RAS), with its main mediator angiotensin II (ANGII). Elevated levels of circulating and intracellular ANGII and aldosterone lead to pro-fibrotic, -inflammatory and -hypertrophic milieu that causes remodelling and dysfunction in cardiovascular and renal tissues. Furthermore, ANGII has been recognized as major risk factor for the induction of apoptosis in podocytes, ultimately leading to chronic kidney disease (CKD). In the past, disease modeling of kidney-associated malignancies was extremely difficult, as the derivation of kidney originated cells is very challenging. Here we describe a differentiation protocol for reproducible differentiation of SIX2-positive urine derived renal progenitor cells (UdRPCs) into mature podocytes bearing typical foot processes. The UdRPCs-derived podocytes show the ability to execute Albumin endocytosis and the activation of the renin-angiotensin system by being responsive to ANGII stimulation. Our data reveals the ANGII dependent downregulation of NPHS1 and SYNPO, resulting in the disruption of the complex podocyte cytoskeletal architecture, as shown by immunofluorescence-based detection of α–ACTININ. In the present manuscript we confirm and propose UdRPCs as a unique cell type useful for studying nephrogenesis and associated diseases. Furthermore, the responsiveness of UdRPCs-derived podocytes to ANGII implies potential applications in nephrotoxicity studies and drug screening.
2022-03-31 | GSE171240 | GEO
Project description:The human placental renin-angiotensin system (RAS) genes encoding for prorenin (REN), angiotensinogen (AGT), prorenin receptor (ATP6AP2) and angiotensin II type I (AGTR1) receptor are upregulated in early gestation and affect placental development. At this time, the placental oxygen tension is at its lowest (1-3%). Some miRNAs predicted to target the RAS are downregulated in early gestation. Our hypothesis is that the low oxygen tension in early pregnancy suppresses expression of miRNAs that target the placental RAS; thus expression of these RAS genes are upregulated. Ten miRNAs predicted to target RAS mRNAs were downregulated in response to 1% vs. 20% oxygen, and six miRNAs were decreased in cells cultured in 1% vs. 5% oxygen.
2018-11-30 | GSE121593 | GEO
Project description:Quiescent C2C12 myoblasts and myoblasts that were stimulated with Angiotensin II for 12 h or 24 h Keywords = Angiotensin II
2004-07-28 | E-GEOD-1592 | biostudies-arrayexpress
Project description:Renin-angiotensin system (RAS) inhibition reduces stroke and improves brain capillary integrity in stroke prone spontaneously hypertensive rats (SHRSP). We tested the hypothesis that treatment with an angiotensin II receptor subtype 1 (AT1R) antagonist has different effects, compared to an angiotensin converting enzyme (ACE) inhibitor, on gene expression in blood-brain barrier (BBB) capillaries. Six weeks old SHRSP were treated with either olmesartan (4 mg/kg, n=20), lisinopril (6 mg/kg , n=20) or remained untreated (n=20). Blood pressure was controlled by tail-cuff measurement. After 5 weeks the animals were sacrificed and cerebral capillaries were isolated. mRNA was extracted and analyzed with rat GeneChip DNA arrays. Additionally, brain histology and monocyte/macrophage infiltrates were determined. Both treatments similarly reduced neurological signs of stroke, stroke mortality, and monocyte/macrophage infiltration, compared to controls. Blood pressure was not influenced significantly by both drugs. We found 42 transcripts that were regulated by both treatments in the same manner. These genes were mostly related to inflammation. We also observed 39 differentially expressed genes between the two treatment groups that typically contribute to cell growth and differentiation. This study demonstrates that, despite similar effects on cerebral pathology and outcome, ACE inhibition and AT1R blockade have distinct molecular effects on gene expression in BBB capillaries.
2007-10-31 | E-GEOD-1548 | biostudies-arrayexpress
Project description:Renin-angiotensin system (RAS) inhibition reduces stroke and improves brain capillary integrity in stroke prone spontaneously hypertensive rats (SHRSP). We tested the hypothesis that treatment with an angiotensin II receptor subtype 1 (AT1R) antagonist has different effects, compared to an angiotensin converting enzyme (ACE) inhibitor, on gene expression in blood-brain barrier (BBB) capillaries. Six weeks old SHRSP were treated with either olmesartan (4 mg/kg, n=20), lisinopril (6 mg/kg , n=20) or remained untreated (n=20). Blood pressure was controlled by tail-cuff measurement. After 5 weeks the animals were sacrificed and cerebral capillaries were isolated. mRNA was extracted and analyzed with rat GeneChip DNA arrays. Additionally, brain histology and monocyte/macrophage infiltrates were determined. Both treatments similarly reduced neurological signs of stroke, stroke mortality, and monocyte/macrophage infiltration, compared to controls. Blood pressure was not influenced significantly by both drugs. We found 42 transcripts that were regulated by both treatments in the same manner. These genes were mostly related to inflammation. We also observed 39 differentially expressed genes between the two treatment groups that typically contribute to cell growth and differentiation. This study demonstrates that, despite similar effects on cerebral pathology and outcome, ACE inhibition and AT1R blockade have distinct molecular effects on gene expression in BBB capillaries. Keywords = angiotensin II Keywords = gene expression Keywords = microarrays Keywords = brain capillaries Keywords = SHRSP Keywords = olmesartan Keywords = lisinopril Keywords: other
2004-08-31 | GSE1548 | GEO
Project description:Quiescent C2C12 myoblasts and myoblasts that were stimulated with Angiotensin II for 12 h or 24 h Keywords = Angiotensin II Keywords: parallel sample
2004-07-28 | GSE1592 | GEO
Project description:The placental renin-angiotensin system (RAS) is important for placentation. RAS expression is greatest in early gestation. This may be due (in part) to suppression of miRNAs that target the placental RAS, but this has never been explored. In this study, human placental miRNAs were measured at 10–11 (early), 14–18 (mid), and 38–40 (term) weeks gestation, as well as in placentae from women with early- or late-onset preeclampsia (n=4/group), using an Agilent miRNA microarray (V19). All miRNAs showed a gestational increase and could influence the transgestational profile of the human placental RAS. Additionally, on the array, three miRNAs predicted to target the RAS (miR-892c-3p, miR-378c and miR-514-3p ) were overexpressed in placentae of late-onset preeclamptic women.
2018-08-21 | GSE109832 | GEO